Qualigen Therapeutics, Inc. - QLGN STOCK NEWS

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Michael Poirier will discuss the company’s oncology pipeline, including promising preclinical results for QN-247 and RAS-F assets. The presentation will be available virtually starting September 13 at 7:00 AM ET and accessible for 90 days. Virtual one-on-one meetings with management will be held during the conference. Qualigen focuses on cancer therapies with potential Orphan Drug Designation and also has a diagnostics division.

Qualigen Therapeutics (Nasdaq: QLGN) shifts focus to its oncology pipeline, including QN-247 and RAS-F, after receiving FDA feedback on its COVID-19 candidate, QN-165. The FDA requested more preclinical studies, prompting the pivot due to the crowded market. Q2 revenue rose 24% to $1.1 million, while the first half saw a 28% increase to $3.0 million. Net loss for Q2 was $5.3 million, down from $18.6 million in 2020. Cash equivalents stood at $15.2 million as of June 30, 2021. Qualigen aims to secure Orphan Drug status for QN-247, enhancing its market position in oncology.

Qualigen Therapeutics (NASDAQ: QLGN) announces the submission of an Investigational New Drug (IND) application for QN-165 to the FDA, targeting COVID-19 treatment in hospitalized patients. QN-165 is a DNA aptamer designed to block viral replication by binding to the nucleolin protein. Chairman and CEO Michael Poirier expressed excitement over this milestone, emphasizing QN-165's unique mechanism that may protect against various virus strains. This marks a significant shift for Qualigen from diagnostics to therapeutics, enhancing its clinical-stage program.

Qualigen Therapeutics (NASDAQ: QLGN) will be added to the Russell Microcap Index at the end of the annual reconstitution on June 28, 2021. This membership signifies progress in its oncology and viral disease pipeline. Membership also ensures automatic inclusion in relevant growth and value indexes, which are significant for institutional investors managing approximately $10.6 trillion in assets. Qualigen's CEO, Michael Poirier, expressed excitement over this milestone, highlighting its implications for investment and growth opportunities.

Qualigen Therapeutics (NASDAQ: QLGN) announced CEO Michael Poirier will present at the LD Micro Invitational XI Conference from June 8-10, 2021. The presentation is scheduled for June 9, 2021, at 12:30 pm PT (3:30 pm ET) in Track 4. It will highlight the company’s therapeutics pipeline aimed at addressing significant unmet needs in cancer and viral diseases, along with the established FastPack® diagnostics line. Attendees can request virtual one-on-one meetings with management.

Qualigen Therapeutics has appointed Tariq Arshad, MD, MBA as the new Senior Vice President, Chief Medical Officer, aiming to enhance their oncology and viral disease pipeline. Dr. Arshad brings over 20 years of experience from top biopharmaceutical companies, including Becton Dickinson and Pfizer. His expertise in immuno-oncology is expected to significantly advance the company's therapeutic programs. This appointment comes at a crucial growth phase for Qualigen, as it develops novel treatments for cancer and viral diseases, including QN-247 and QN-165.

Qualigen Therapeutics (Nasdaq: QLGN) reported a 30% revenue increase to $1.9 million for Q1 2021, up from $1.5 million in Q1 2020. This growth was driven largely by license revenue from their FastPack® System, particularly from a deal with Yi Xin Duan Jishu in China. As of March 31, 2021, the company had approximately $21.9 million in cash. Qualigen is on track to file an IND in 2H21 for QN-165, an antiviral for COVID-19, and completed R&D for QN-247. Increased administrative expenses rose to $2.9 million due to public company overhead.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced that Michael Poirier and Amy Broidrick will present at the Benzinga Biotech Small Cap Conference on March 24, 2021. The presentation is scheduled for 11:35 am – 11:55 am EDT.

Qualigen develops therapies for cancer and infectious diseases, including promising candidates like ALAN, RAS-F, and STARS. Their FDA-approved FastPack® System is used for diagnostic tests worldwide. Interested investors may request one-on-one meetings through conference hosts.

Qualigen Therapeutics (Nasdaq: QLGN) has promoted Shishir Sinha to Chief Operating Officer, enhancing its leadership in drug development. Sinha, a 15-year veteran of the company, will leverage his expertise to oversee therapeutics project management. Qualigen focuses on developing therapeutics for cancer and infectious diseases while maintaining its FastPack System for diagnostics. Their product pipeline includes ALAN, RAS-F, and STARS. Despite advancements, challenges in clinical trials and regulatory approvals remain, posing risks to stock performance.